{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:45:45Z","timestamp":1784425545113,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.02.031","type":"journal-article","created":{"date-parts":[[2014,3,15]],"date-time":"2014-03-15T06:45:38Z","timestamp":1394865938000},"page":"2799-2804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Rabies virus-like particles expressed in HEK293 cells"],"prefix":"10.1016","volume":"32","author":[{"given":"Diego","family":"Fontana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Kratje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Etcheverrigaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.031_bib0005","first-page":"425","article-title":"Rabies vaccines WHO position paper","volume":"49","author":"World Health Organization","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrmicro2260","article-title":"The cell biology of rabies virus: using stealth to reach the brain","volume":"8","author":"t;S Schnell","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"RR-3","key":"10.1016\/j.vaccine.2014.02.031_bib0015","article-title":"Human Rabies Prevention","volume":"57","author":"Center for Disease Control and Prevention","year":"2008","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1743-422X-9-50","article-title":"Rabies molecular virology, diagnosis, prevention and treatment","volume":"9","author":"Yousaf","year":"2012","journal-title":"Virol J"},{"issue":"9","key":"10.1016\/j.vaccine.2014.02.031_bib0025","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1371\/journal.pntd.0000515","article-title":"Novel vaccines to human rabies","volume":"3","author":"Ertl","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2014.02.031_bib0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0035","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/eji.201142064","article-title":"Virus-like particles induce robust human T-helper cell responses","volume":"42","author":"Braun","year":"2011","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2014.02.031_bib0040","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0045","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rvsc.2011.10.018","article-title":"Virus-like particles: potential veterinary vaccine immunogens","volume":"93","author":"Liu","year":"2011","journal-title":"Res Vet Sci"},{"issue":"9","key":"10.1016\/j.vaccine.2014.02.031_bib0055","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1128\/JVI.62.9.3128-3134.1988","article-title":"Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients","volume":"62","author":"Celis","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0060","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1099\/0022-1317-68-4-1115","article-title":"T cell clones directed to rabies virus: isolation and some of their properties","volume":"68","author":"Cho","year":"1987","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.02.031_bib0065","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/IAI.16.3.754-759.1977","article-title":"Rabies virus glycoprotein: II. Biological and serological characterization","volume":"16","author":"Cox","year":"1977","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-387040-7.00002-0","article-title":"Rabies virus assembly and budding","volume":"79","author":"Okumura","year":"2011","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0075","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0092-8674(00)81072-7","article-title":"Budding of rabies virus particles in the absence of the spike glycoprotein","volume":"84","author":"Mebatsion","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0080","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.vaccine.2012.02.015","article-title":"Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines","volume":"30","author":"Hess","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0085","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1016\/j.vaccine.2010.03.029","article-title":"Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing","volume":"28","author":"Le Ru","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2014.02.031_bib0090","doi-asserted-by":"crossref","first-page":"e18437","DOI":"10.1371\/journal.pone.0018437","article-title":"Vaccine potential of Nipah virus-like particles","volume":"6","author":"Walpita","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jviromet.2010.07.015","article-title":"Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles","volume":"169","author":"Mandell","year":"2010","journal-title":"J Virol Methods"},{"issue":"14","key":"10.1016\/j.vaccine.2014.02.031_bib0100","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1128\/JVI.00421-09","article-title":"Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles","volume":"83","author":"Li","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","article-title":"A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","volume":"397","author":"Mandell","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jviromet.2007.12.004","article-title":"The creation of stable cell lines expressing Ebola virus glycoproteins and the matrix protein VP40 and generating Ebola virus-like particles utilizing an ecdysone inducible mammalian expression system","volume":"148","author":"Melito","year":"2008","journal-title":"J Virol Methods"},{"issue":"1","key":"10.1016\/j.vaccine.2014.02.031_bib0115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00253-012-3958-7","article-title":"Dengue virus-like particles: construction and application","volume":"94","author":"Shang","year":"2012","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.copbio.2007.10.013","article-title":"Virus-like particles \u2013 universal molecular toolboxes","volume":"18","author":"Ludwig","year":"2007","journal-title":"Curr Opin Biotechnol"},{"issue":"8","key":"10.1016\/j.vaccine.2014.02.031_bib0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1753-6561-5-S8-P7","article-title":"A strategy to obtain recombinant cell lines with high expression levels, Lentiviral vector-mediated transgenesis","volume":"5","author":"Prieto","year":"2011","journal-title":"BMC Proc"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0130","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2014.02.031_bib0140","series-title":"Briefing document \u2013 testing for replication competent retrovirus (RCR)\/lentivirus (RCL) in retroviral and lentiviral vector based gene therapy products \u2013 revisiting current FDA recommendations","author":"FDA","year":"2006"},{"issue":"3","key":"10.1016\/j.vaccine.2014.02.031_bib0145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/mt.2010.278","article-title":"Replication-competent lentivirus analysis of clinical grade vector products","volume":"19","author":"Cornetta","year":"2009","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2014.02.031_bib0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1586\/erv.11.37","article-title":"Virus-like particles: innate immune stimulators","volume":"10","author":"Raghunandan","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"23","key":"10.1016\/j.vaccine.2014.02.031_bib0155","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.vaccine.2010.03.039","article-title":"The immune response to rabies virus infection and vaccination","volume":"28","author":"Johnson","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T09:45:01Z","timestamp":1597571101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":31,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14002047"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rabies virus-like particles expressed in HEK293 cells","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}